AGXT

Across TCGA pan-cancer cohorts, AGXT mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of AGXT’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AGXT mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AGXT is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC and LUAD are the cancer types where AGXT tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AGXT mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	−1.473	<.001	11	view →
LUAD	Female	All	−1.303	.003	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

AGXT–CCRCC

Open the CCRCC breakdown →